SecBot SecBot
8-K ·Filed Apr 13, 2026

TVTX

Travere Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001438533-26-000032
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

FILSPARI's approval in FSGS creates a new standard of care and first-mover advantage in a rare disease with no prior approved treatments. Traders should monitor commercial ramp-up and potential pricing power, while watching for competitive responses. Consider this a major value inflection given the expanded addressable market.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$42.13
T+0 close · Apr 13, 2026 · via day close
Latest settled
+38.78%
T+60 · $58.47
Vs SPY
+30.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $42.13entry
  2. T+1 · 7mo ago −2.80%α −3.58% · $40.95
  3. T+5 · 7mo ago −7.95%α −9.35% · $38.78
  4. T+20 · 6mo ago +3.28%α −3.02% · $43.51
  5. T+60 · 4mo ago +38.78%α +30.26% · $58.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Travere Therapeutics (TVTX) announced FDA approval of FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first and only FDA-approved treatment for FSGS, expanding FILSPARI's label beyond IgA nephropathy.

Key Facts

  • FDA approved FILSPARI for FSGS without nephrotic syndrome in patients aged 8 and older
  • FILSPARI is the first and only FDA-approved treatment for FSGS
  • Approval expands FILSPARI's label beyond IgA nephropathy into a second rare kidney disease
  • Phase 3 DUPLEX study showed 48% reduction in proteinuria vs 27% for irbesartan in non-nephrotic FSGS patients
  • Company estimates U.S. addressable population exceeds 30,000 individuals with FSGS without nephrotic syndrome

Financial Impact

Potential blockbuster expansion: FILSPARI now addresses >30,000 additional U.S. FSGS patients without nephrotic syndrome, significantly expanding its commercial opportunity beyond IgA nephropathy

revenuemarket sharedrug pricing power

Risk Factors

  • Commercial execution risk in launching and marketing to a new patient population
  • Potential payer reimbursement challenges for a high-cost rare disease drug
  • Safety profile monitoring in broader patient population
  • Future competition from emerging FSGS therapies in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001438533-26-000032
Document: 0001438533-26-000032-index-headers.html0001438533-26-000032
Document: 0001438533-26-000032-index.html0001438533-26-000032
Document: 0001438533-26-000032.txt0001438533-26-000032

Track record

21 reports on TVTX

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  5. Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
  6. Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
  7. Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  8. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  9. Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
  10. Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026